• If you are using hotmail, outlook, live or rediffmail email and are trying to register or have registered with the website, please read this post.
  • Welcome to Tamil Brahmins forums.

    You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. By joining our Free Brahmin Community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, join our community today!

    If you have any problems with the registration process or your account login, please contact contact us.

Haryana health minister Anil Vij gets trial dose of India-made Covaxin on Friday

ashok68

Member

May be a good initiative giving confidence among other volunteers…​

Hope standard testing procedures are followed.​

Haryana health minister Anil Vij gets trial dose of India-made Covaxin on Friday​

1605860721059.png

Anil Vij being administered a trial dose of Covaxin at a hospital in Ambala. (ANI)
----------------------------------------------------------------------------------------------

Haryana Health Minister and BJP leader Anil Vij, who had offered to be the first volunteer in the phase three trials for potential coronavirus vaccine Covaxin, has been administered a trial dose on Friday.

Vij was administered the trial dose at the Civil Hospital at Ambala Cantt, the BJP leader said on Twitter.

Earlier in a tweet, Ani Vij said: "I will be administered a trial dose of Coronavirus vaccine #Covaxin a Bharat Biotech product Tomorrow at 11 am at Civil hospital, Ambala Cantt under the expert supervision of a team of doctors from PGI Rohtak and Health Department. I have volunteered to take the trial dose."

On 18 November, the Ambala Cantt MLA had said the third phase of trial of Covaxin will begin in Haryana on 20 November and had offered to be the first volunteer to get vaccinated.

"Trial for third phase of Covaxin a coronavirus vaccine product of Bhart Biotech to start in Haryana on 20th November. I have offered myself as first volunteer to get vaccinated," Haryana Health Minister Anil Vij tweeted.

………………………………

Vaccine maker Bharat Biotech had earlier announced the commencement of phase-3 trials of Covid-19 vaccine Covaxin. The phase-3 trials will involve 26,000 volunteers across India and will be conducted in partnership with ICMR.

Also, volunteers who wish to participate in this trial should be adults over 18 years of age.

The company earlier said that it has successfully completed interim analysis of Phase 1 and 2 trials and is working on Phase 3 trials.

This is the largest clinical trial conducted for a Covid-19 vaccine in the country.

Read more at:

 

ashok68

Member

The whole world is waiting eagerly for an effective vaccine to fight the coronavirus pandemic. It has not only claimed lives, but also impacted people, both physically and mentally. It is reported that there are more than 170 vaccines in progress right now, but closer home we have our hopes pinned on India’s first vaccine called Covaxin.​

Vaccine progress: Vaccines for Covid are in sight, but safely riding out this winter is critical​

With November bringing encouraging results on vaccine trials, focus must now shift to rapidly expand the infrastructure needed for vaccine delivery. Ongoing Phase 3 trials of the cutting edge mRNA vaccines developed by Pfizer-BioNTech and Moderna are pointing to efficacy rates as high as 95%. Russia has also claimed nearly similar effectiveness for its Sputnik V vaccine in late stage trials. One Chinese vaccine candidate CoronaVac has passed early trials for safe, adequate immune response amid concerns over lower levels of neutralising antibody presence compared to recovered Covid patients.

So far India has booked 1.6 billion doses with Novavax-SII, Oxford-AstraZeneca-SII whose Phase 3 trial results are expected soon, and Gamaleya Institute which developed Sputnik V. Indian companies like Bharat Biotech and Zydus Cadila are also in the race. While the fast progress in trials is a morale booster, a long timeline for vaccinating the general population beckons. Prioritisation for health staff and other vulnerable groups and ramping up production facilities and cold chains could stagger the process in India. During the interim, improvements in treatment protocols are key to reducing mortality.

…………………………………………..

Meanwhile, there is no room for complacency despite the impending vaccines. The ongoing global spurt of infections this winter is likely the biggest crisis moment in the pandemic. Delhi’s current hospital and ICU bed situations are behind the curve. A national spike of similar scale could overpower states with poor public health capacity. With lockdowns no more an option, governments must keep several balls up in the air: bolstering reliable testing, ICU bed capacity, vaccine logistics and the economy. Citizens must do their part too: by exercising caution and good sense in their social interactions by face masking and physical distancing.


Read more at:
 

ashok68

Member
Covid vaccine should be available for public by April 2021:

NEW DELHI: Vaccine maker Serum Institute of India's CEO Adar Poonawalla on Thursday said the Oxford Covid-19 vaccine should be available for healthcare workers and elderly people by around February 2021 and by April for the general public, and will be priced at a maximum of Rs 1,000 for two necessary doses . for the public, depending on the final trial results and regulatory approvals.


Read more at:
 

ashok68

Member

போட்டா போட்டி போடும் கரோனா தடுப்பூசிகள்!​


1605954792058.png

கரோனா தடுப்பூசி உருவாக்கத்தில் உலக நாடுகளிடையே போட்டா போட்டி நிலவுகிறது. இதுவரை 11 கரோனா தடுப்பூசிகள் மக்களின் நம்பிக்கையைப் பெறும் விதத்தில் அமைந்துள்ளன. அமெரிக்காவின் பைசர் (Pfizer) நிறுவனமும் ஜெர்மனியின் பயோஎன்டெக் நிறுவனமும் இணைந்து ‘BNT162b2’ கரோனா தடுப்பூசியைத் தயாரித்துள்ளன. மூன்றாம் கட்ட ஆய்வில் இருக்கும் இத்தடுப்பூசி 90 சதவீத பலன் தருவதாகவும் அவசரப் பயன்பாட்டுக்கு அமெரிக்க உணவு மற்றும் மருந்து நிர்வாகத்தின் (FDA) அனுமதி கேட்க இருப்பதாகவும் இந்த நிறுவனங்கள் சமீபத்தில் அறிவித்தன.

தங்களது ‘ஸ்புட்னிக்-வி’ தடுப்பூசி 92 சதவீத பலன் தருவதாக அடுத்த இரண்டு நாள்களில் ரஷ்யா அறிவித்தது. இந்த வாரம், அமெரிக்காவின் மாடர்னா நிறுவனம் தயாரித்துள்ள ‘எம்ஆர்என்ஏ-1273’ (mRNA-1273) தடுப்பூசி 94.5 சதவீதச் செயல்திறன் கொண்டுள்ளதாகத் தெரிவித்து, உலக மக்களிடம் அதிக எதிர்பார்ப்பையும் பரபரப்பையும் ஏற்படுத்தியுள்ளது.

Read more at

 

ashok68

Member
Every day counts!

Where does it stand??

Covid vaccine update: PM-CMs meet over vaccine; 1st US citizen may get a shot in Dec | More

1606103642456.png

A nurse prepares Covid-19 vaccine to administer to a volunteer. (File photo: AP)
----------------------------------------------------------------------------------------------------------------


The race for a vaccine to beat the novel coronavirus is on, not just in India, but in the entire world. While first US citizens could receive Covid-19 vaccine shot by December 11-12, in India, Prime Minister Narendra Modi will hold virtual meetings with chief ministers and other representatives of states and union territories on Tuesday to discuss the vaccine distribution strategy, reports suggested.

In another development, Niti Aayog member Vinod Paul said on Saturday that India may grant emergency use authorisation of Oxford-AstraZeneca coronavirus vaccine to Pune-based Serum Institute of India (SII) if AstraZeneca gets such approval from the UK government. Paul also said that if the clinical trials of the coronavirus vaccine in India go as per the script, phase III trials should be over by January-February 2021.

Meanwhile, leaders of the 20 biggest economies vowed on Sunday to spare no effort to supply Covid-19 drugs, tests and vaccines affordably and fairly to “all people”, reflecting worries that the pandemic could deepen divisions between the world’s rich and poor.

Here are the latest developments in the race for coronavirus vaccine:


Read more at:
 
Top
  Thank you for visiting TamilBrahmins.com

You seem to have an Ad Blocker on.

We depend on advertising to keep our content free for you. Please consider whitelisting us in your ad blocker so that we can continue to provide the content you have come here to enjoy.

Alternatively, consider upgrading your account to enjoy an ad-free experience along with numerous other benefits. To upgrade your account, please visit the account upgrades page

You can also donate financially if you can. Please Click Here on how you can do that.